Clinical Trials Browser

Phase 2 × olaratumab × Gastrointestinal × Clear all

NCT01316263 2017-03-09

A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Phase 2 Terminated

21 enrolled 24 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors